Peptide targeted gold nanoplatform carrying miR-145 induces antitumoral effects in ovarian cancer cells
Author
dc.contributor.author
Salas Huenuleo, Edison Sebastián
Author
dc.contributor.author
Hernández Jorquera, Andrea Carolina
Author
dc.contributor.author
Lobos González, Lorena
Author
dc.contributor.author
Polakovicová, Iva
Author
dc.contributor.author
Morales Zavala, Francisco Andrés
Author
dc.contributor.author
Araya, Eyleen
Author
dc.contributor.author
Celis, Freddy
Author
dc.contributor.author
Romero Osses, Carmen Aurora
Author
dc.contributor.author
Kogan, Marcelo Javier
Admission date
dc.date.accessioned
2023-11-21T14:27:30Z
Available date
dc.date.available
2023-11-21T14:27:30Z
Publication date
dc.date.issued
2022
Cita de ítem
dc.identifier.citation
Pharmaceutics 2022, 14, 958
es_ES
Identifier
dc.identifier.other
10.3390/pharmaceutics14050958
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/196450
Abstract
dc.description.abstract
One of the recent attractive therapeutic approaches for cancer treatment is restoring downregulated microRNAs. They play an essential muti-regulatory role in cellular processes such as proliferation, differentiation, survival, apoptosis, cell cycle, angiogenesis, and metastasis, among others. In this study, a gold nanoplatform (GNPF) carrying miR-145, a downregulated microRNA in many cancer types, including epithelial ovarian cancer, was designed and synthesized. For targeting purposes, the GNPF was functionalized with the FSH33 peptide, which provided selectivity for ovarian cancer, and loaded with the miR-145 to obtain the nanosystem GNPF-miR-145. The GNPF-mir-145 was selectively incorporated in A2780 and SKOV3 cells and significantly inhibited cell viability and migration and exhibited proliferative and anchor-independent growth capacities. Moreover, it diminished VEGF release and reduced the spheroid size of ovarian cancer through the damage of cell membranes, thus decreasing cell viability and possibly activating apoptosis. These results provide important advances in developing miR-based therapies using nanoparticles as selective vectors and provide approaches for in vivo evaluation.
es_ES
Patrocinador
dc.description.sponsorship
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)
CONICYT FONDECYT 1160139
3190547
1190623
1211482
PAI 77200057
Fondap 15130011
es_ES
Lenguage
dc.language.iso
en
es_ES
Publisher
dc.publisher
MDPI
es_ES
Type of license
dc.rights
Attribution-NonCommercial-NoDerivs 3.0 United States